Stop Doing
Business with Russia
Russia initiated aggression against Ukraine in 2014. On February 24, 2022, it started a full-scale military invasion to the Ukrainian territory. This brutal war and military crimes of Russian troops caused a humanitarian crisis in Ukraine with thousands civilians killed and millions becoming refuges. As a reaction to this act of aggression, many international companies decided to leave the Russian market, while some others continue doing business there as usual. We track such decisions of companies and urge them to stop funding the war.
Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business
Pausing InvestmentsReducing Activities: company scaling back some business operations while continuing others
Scaling BackPause operations: company temporarily curtailing operations while keeping return options open
SuspensionClean Break: the company completely halting Russian engagements or exiting Russia
WithdrawalExit Completed: company sold its business/assets or its part of the business to a local partner and leaved the market or liquidated local entity(ies)
Exit Completed
The company promised to stop new investments in Russia. It is continuing to work in Russia, and are taking all required measures to ensure an uninterrupted supply of medicines. Despite the statements of international pharmaceutical companies about the suspension of new tests in Russia after the start of military operations in Ukraine, the British-Swedish AstraZeneca will conduct a study of a new drug for the prevention of COVID-19 in the Russian Federation, which is necessary before its registration. AstraZeneca has spent about £45 million to pay Russian doctors since Moscow invaded and its chief said ‘medicines are never under sanctions’. AstraZeneca was the main sponsor of a major summit on bringing European businesses back to Russia - the 21st Association of European Businesses in Russia event. Revenue increased in 2024 vs 2023 by more than +30%.
The company promised to stop any new spending not related to the supply of the essential and life-changing medicines and vaccines in Russia, as well as in Belarus. Increased revenue, profit and assets in Russia in 2022 vs 2021. Customs data shows that the latest deliveries were in 2023. Sanofi experiencing serious supply problems from its Russian plant to EU market.
Still operating in Russia. Paid $42 mn of taxes in 2022.
Pfizer will donate all profits of the Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine. There will be no new clinical trials in Russia. Stopped new investments in Russia. The pharmaceutical company Pfizer has not ceased and continues its activities in Russia despite everything, its press service told RBC. This is how the company responded to the inclusion of the company by the Center for Strategic Research (CSR) in the list of foreign enterprises that have no chance of returning to the Russian market. "Pfizer has been providing uninterrupted supplies of medicines for patients in Russia for all these years," the company said.
Teva in Russia is working in its standard operating mode
Received revenues in Russia in 2022.
Will continue to supply essential medicines, vaccines, medical devices, and equipment in Russia. Halted clinical trials, advertising, and promotion. Russian sales proceeds to go to humanitarian aid (no manufacturing and little raw materia/suply chain reliance). Still operating in Russia with increasing sales and profit volumes in 2022 vs 2021. After the start of Russia's war against Ukraine, the volume of product exports to Russia increased.
Office in Russia. Received revenues in Russia in 2022-2024. Dr Reddy’s Laboratories Ltd has infused ₹565.4 crore into its Russian arm, Dr Reddy’s Laboratories LLC (DRL Russia), acquiring a 45.19% equity stake in the step-down wholly-owned subsidiary. The investment, made on July 25, 2025, follows board approval granted on November 5, 2024, to inject up to ₹600 crore into the Russian entity. The capital was infused via cash and will be used to support DRL Russia’s working capital requirements. DRL Russia, which operates as a pharmaceutical distribution company in the Russian Federation, reported a turnover of ₹2,347 crore in FY25.
Still operating in Russia
Have decided to suspend any investment in Russia as well as commercial marketing activities. The company did not stop working in Russia. The Russian website is working. In October 2023, the general director was changed. Staff are being recruited.
Continue to supply patients, not for fianacial reasons
Significantly increased revenue, profit and taxes paid in Russia in 2022 vs 2021. Revenue increased in 2024 vs 2023 by more than +30%.
Company was originally founded in St. Petersburg, over $60 milllion exports to Russia after February 24, 2022. In 2022 $28 million exports to Russia, or 28% of that year revenue. Increased revenue and profit in 2022 vs 2021.
Continue operating subsidiary in Russia but limited some activities. Revenue increased in 2024 vs 2023 by more than +50%.
AbbVie has temporarily suspended operations for the aesthetics products in Russia and paused the start of new clinical studies. Other operations are continued. Revenue increased in 2024 vs 2023 by more than +50%.
No relevant news about leaving Russia.
German pharmaceutical company Bionorica put up for sale an unfinished plant in Voronezh. The fact that the German pharmaceutical company Bionorica began looking for buyers for its plant for the production of drugs in Voronezh, was told by a source close to the company that was considering the acquisition of this enterprise. According to him, the decision to sell is related to the sanctions restrictions imposed by the European Union on Russia, as a result of which the import of foreign raw materials and special equipment necessary for the production of medicines into Russia has become impossible. Nevertheless, Bionorica is still operating in Russia with a Hufe Sales team, importing pharmaceuticals from the German headquarter. Revenue increased in 2024 vs 2023 by more than +100%.
Russian website works
No official statement
Business as usual
Italy's Recordati boosted by strong sales in Russia. Italian drug maker Recordati benefited from strong demand in markets such as Turkey and Russia in the first three months of the year, its chief executive said on May 11, 2023 after the company lifted its annual revenue and profit targets. Koremans said that Recordati did not produce any products in Russia but continued to import treatments for rare diseases, as well as prescription drugs for more routine conditions.
Received revenues in Russia in 2021-2024, there is no any official announcement. Revenue increased in 2024 vs 2023 by more than +30%.
No official statement
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2022-2024. Zentiva sells operations in Russia and CIS markets, no details disclosed officially so far. Revenue increased in 2024 vs 2023 by more than +30%.
No official statement
No official statement
Продовжують працювати як зазвичай.
A subsidiary of the Indian Jodas Expoim, filed a lawsuit in the Arbitration Court of the Moscow Region to oblige the Iranian AryoGen Pharmed to supply the drug. 06.2024: Internal transfer. The entry about the founder of the LIMITED LIABILITY COMPANY JODAS EXPOIM PRIVATE LIMITED was removed from the Unified State Register of Legal Entities. JODAS EXPOIM PRIVATE LIMITED becomes the new founder of the organization.
Group's financials says considers Russia a main market. Revenue and profit skyrocketed in 2022 vs 2021.
Continue doing business as usual.
Continue doing business as usual, increased revenue in 2022 vs 2021. Revenue increased in 2024 vs 2023 by more than +50%.
Received revenues in Russia in 2021, there is no any official announcement
Continue doing business as usual.
The pharma giant Grindeks exporting to Belarus, whereas its subsidiary Kalceks exports to Russia. Grindeks' turnover in 2022 was EUR 258 million, of which EUR 70.6 in Russia.
Received revenues in Russia in 2021, there is no any official announcement
Still operating in Russia
No official statement
No official statement
Continuing business in Russia and exports. Customs data shows that the latest deliveries were in 2023.
Continues sales in Russia
No official statement
Received revenues in Russia in 2021, there is no any official announcement
No official statement
Continue doing business as usual.
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
No official statement
No official statement
SA's Aspen to keep supplying Russia with medicines
Continuing business in Russia and exports, increased revenue and profit in 2022 vs 2021.
Received revenues in Russia in 2021-2024, there is no any official announcement. Revenue increased in 2024 vs 2023 by more than +50%.
Chiesi Group plans to maintain operations in the Russian territories, focusing primarily on medical information and disease awareness and ensure access to our therapeutic options. Chiesi Group is however temporarily pausing any new recruitment of patients for all ongoing clinical trials in Russia, though continuing to treat all those already enrolled and ensuring they receive all the therapeutic solutions they need. "Our focus will always remain on our patients, and Chiesi will continue to prioritise uninterrupted access to treatments to patients in Ukraine and Russia and surrounding territories, despite the unstable situation."
Very important, Neo-Angin and Nasic make big profits for Medice, pharmreg.ru and Items. Increased russia-driven revenue and profit in 2023 vs 2022. LLC "Medice" in Moscow is the local representative.
Received revenues in Russia in 2021-2024, there is no any official announcement. Revenue increased in 2024 vs 2023 by more than +30%.
Received revenues in Russia in 2021, there is no any official announcement
The company continues to work in Russia. Cadila Pharmaceuticals met in 2023 with the Deputy Prime Minister of the Russian Federation and the Minister of International Relations of the Government of Moscow at a powerful bilateral industry round table in New Delhi/ 20224 hsr The Russian Direct Investment Fund (RDIF) and Cadila Pharmaceuticals Ltd., one of the leading private Indian pharmaceutical corporations, have agreed on joint investments in a project to create an innovative pharmaceutical complex and a plant for injectable drugs in Russia.
Received revenues in Russia in 2021-2023, there is no any official announcement. On April 28, 2025 the Ministry of Health held the first meeting in 2025 of the commission for the formation of lists of vital drugs (VED) and 14 high-cost nosologies (HCN). The commission also included pegcetacoplan (Empaveli from Swedish Orphan Biovitrum AB) in the list of VED.
Received revenues in Russia in 2021, there is no any official announcement
Received revenues in Russia in 2021, there is no any official announcement
“Coping with the consequences of pandemic, followed by the war in Ukraine and our exit from Russia, our organisation has focused on improving commercial and operational excellence." Revenue increased in 2024 vs 2023 by more than +30%.
Still operating in Russia
No official statement
Received revenues in Russia in 2021, there is no any official announcement
Still operating in Russia.
Received revenues in Russia in 2022.
No statement made regarding Russian operations, Operating out of its office in Moscow
Promomed, a Russian biopharmaceutical company, Ogarev Mordovian State University, and the Al Riyadh Group, a company based in the Kingdom of Bahrain, signed a trilateral memorandum of understanding (MoU) at the 28th St. Petersburg International Economic Forum (SPIEF-2025). The parties agreed to collaborate on developing pharmaceutical production, training scientific and industrial personnel, and supplying vital drugs to Al Riyadh Group’s distribution network, which operates across the Middle East, Africa, and Latin America.
Identified by YouControl as one of TOP companies with foreign shareholders which have been registered in Russia after the invasion to Ukraine was started. The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Bahrain’s Mumtalakat Holding Company (Mumtalakat, sovereign wealth fund of the Kingdom of Bahrain) and Binnopharm Group (а subsidiary of Sistema PJSFC, a publicly traded Russian investment company) on June 3, 2021 signed a Memorandum of Understanding (MoU) to establish a new vaccine production facility in the Kingdom of Bahrain to manufacture and distribute the Russian Sputnik V coronavirus vaccine across the MENA region.
Bangkok Dusit Medical Services (BDMS) and Russia's Medsi Group have signed a Memorandum of Understanding (MoU) to expand cooperation between the two largest private healthcare providers in Thailand and Russia.
Company continues to do business as usual in Russia and hiring employees.
Last year, Belupo achieved sales of 230 million kunas in the markets of Eastern Europe (mainly in Russia), which is 4.1 percent more than the year before, that is, before the Russian aggression.
The US has imposed export restrictions on 37 companies, nearly 30 of them Chinese, for activities that include aiding the Russian military and supporting China's PLA. The restrictions affected divisions of the Chinese genetics company BGI and the Chinese cloud computing company Inspur.
Ryongaksan Technology Trading Company and Chongryu Moran Trading Company filed trademark applications with Russia’s intellectual property regulator (Rospatent) earlier this month, likely in preparation for exporting their products. Both Pyongyang-based firms registered black-and-white logos: Chongryu’s logo features mountains along with the Mannyonsan trademark, while Ryongaksan’s logo features a horse with a rider on a globe and its own name.
Received revenues in Russia in 2021, there is no any official announcement
On April 18, 2025 Daewoong announced that it has filed for marketing authorization for Enblo in six Latin American countries, including Costa Rica, Honduras, the Dominican Republic, Panama, El Salvador, and Guatemala, as well as in Russia.
El'Pharm was selling the Russian drug Cortexin, which is manufactured by Geropharm in the Moscow region, and medicines produced by Western companies specifically for the Russian market: "Atarax by the Belgian company UCB Pharma and Vobenzyme by the German company Mucos Pharma.
A partnership agreement has been signed between EOC Vietnam Pharmaceutical Co. (EOC) and Russian Good Distribution Partners LLC (GDP). The main goal of the partnership is to create a joint center for the promotion of pharmaceutical products of Russian and Vietnamese companies in the markets of both countries.
EuBiologics signed another technology transfer agreement and contract to supply raw materials for its meningococcal quadrivalent vaccine to Nanolek, a Russian biopharmaceutical.
The complex regulations gave US firms an advantage enabling companies like General Electric Healthcare to actually increase export volumes to Russia, replacing European competitors.
No statement made regarding Russian operations. Continues to operate out of its office in Russia supplying chemical free medicine. Deputy Country Manager at Herbion Russia is still working and is responsible for the business development in Volga Region.
The company continues to work in Russia. It is satisfied with the robot in both countries, as well as in Ukraine and Russia.
"Petrovax," formerly owned by Vladimir Potanin's "Interros" until last year, has reached an agreement with the Chinese company Jiangsu Hengrui regarding the supply and subsequent localization of several oncology drugs, including camrelizumab, belonging to the same class as the American MSD's "Keytruda."
Binnopharm Group will begin sales in Russia of the botulinum toxin Lantox from the Chinese Lanzhou Biotechnique Development (LBD) in August 2024.
The company supplies its productions to its partners in Russia (LLC "NDA Business Medical Company" and LLC "Firma "Finko").
The Madras Diabetes Research Foundation (MDRF), a Global Leader in Diabetes Research, has entered into a strategic research collaboration with the Almazov National Medical Research Centre, based in Saint Petersburg, Russia. This partnership marks a significant step toward advancing international research in diabetes and its related fields.
The Chinese manufacturer of tomographs MinFound registers its products in Russia, and R-Pharm, founded by Alexey Repik, can handle its distribution.
In February 2025, North Korean company Moksong Trading Company was able to obtain approval for its trademark registration in Russia. The application stated the intention to export medical products to Russia — analgesics, disinfectants and antibiotics. Moksong's range of activities is extremely broad, since the company, along with human medicines, was developing feed additives for animals and helping to increase the livestock in North Korea. The company's name coincides with the name of a company under US sanctions, which was accused of participating in the proliferation of weapons.
NanoString Technologies is a key distributor and evader of international sanctions regarding the sale and distribution of biotech research equipment.
Received revenues in Russia in 2021, there is no any official announcement
Russian subsiduary OCTAFARMA-PHARMIMEX LLC is active, they are building a pharmaceutical enterprise "Octapharma-Pharmimex" in the Skopinsky district of the Ryazan region.
Despite sanctions and other risks related to business with Russia, many Latvian companies still export to this country. Recently, the Central Statistical Bureau (CSB) published a list of businesses continuing exports to Russia after the war began. Latvian pharmaceuticals giant Olainfarm is also on the list, whose turnover data for 2022 are not available. Olainfarm sent LTV a plan to enter new markets while emphasizing that it's allowed to export medicines to Russia.
The Russian authorities are discussing the possibility of introducing barrier duties of 220% on dietary supplements from unfriendly countries. The measure may affect such large manufacturers as Stada, Solgar, Unipharm, Pharmamed.
The company continues its business in Russia (via PRO.MED.CS Marketing LLC or ТОВ "ПРО.МЕД.ЦС Маркетинг") as it was before and keeps low profile.
Krasnodar company "Gradient" imports to Russia the injectable dietary supplement "Kumdan-2", produced by North Korean Pugang Pharmaceutical Corporation, according to data from the Federal Accreditation Service. The DPRK authorities advertise this product as a universal cure for all diseases - MERS, SARS and even HIV/AIDS.
Continue operations with Russia.
Ryongaksan Technology Trading Company and Chongryu Moran Trading Company filed trademark applications with Russia’s intellectual property regulator (Rospatent) earlier this month, likely in preparation for exporting their products. Both Pyongyang-based firms registered black-and-white logos: Chongryu’s logo features mountains along with the Mannyonsan trademark, while Ryongaksan’s logo features a horse with a rider on a globe and its own name.
The company Sentro Group acquired a controlling stake in the Russian bank "Mir Privilege". Sentro Group bought 50.001% of the bank's shares, the transaction amount is not disclosed.
Mumbai pharma company Shreya helping Russia get Nvidia AI chips. Exports by Shreya to Russia "perfectly" legal.
The Russian authorities are discussing the possibility of introducing barrier duties of 220% on dietary supplements from unfriendly countries. The measure may affect such large manufacturers as Stada, Solgar, Unipharm, Pharmamed.
The American company Eli Lilly will transfer its Russian business to the Swiss company Swixx Biopharma. Previously, Swixx Biopharma received the business of another American pharmaceutical company, Bristol-Myers Squibb (BMS). The American Eli Lilly banned the Swiss Swixx BioPharma, which a year ago bought Eli Lilly’s business in Russia, from supplying Humalog insulin to the country.
One of the most popular antiviral drugs in Russia, Valenti Pharm's "Ingavirin", which is included in the treatment protocols for the coronavirus, may have the first generic in Russia. Its release is planned by "Basis-Metygreens" together with the Indian Synmedic.
The Russian Direct Investment Fund (RDIF) announced at the St. Petersburg International Economic Forum (SPIEF-2025) the expansion of cooperation with the leading Vietnamese multidisciplinary corporation, T&T Group.
The Russian authorities are discussing the possibility of introducing barrier duties of 220% on dietary supplements from unfriendly countries. The measure may affect such large manufacturers as Stada, Solgar, Unipharm, Pharmamed.
The American company Varian, which supplies used Truebeam linear accelerators for radiation therapy to Russian oncology clinics, is now required to obtain an export license from the US authorities, a process that takes a minimum of three months.
Had a plant in Russia right before invasion, sell their medicines and never made statements about invasion or the cessation of its activities.
Ukraine has found Indian components in Iranian-designed Shahed 136 drones used by Russian troops in the war, said Andriy Yermak, head of the Presidential Office. The drone's power supply unit contained a bridge rectifier assembled in India from the international company Vishay Intertechnology, and the satellite navigation antenna contained a chip from the republic's Aura Semiconductor.